x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Business Of Biotech

The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business

business management

All Episodes

46:43

Deal And Investment Trends With Investment Banker...

Business Of Biotech ·

2025/04/07

We love to hear from our listeners. Send us a message. Today we're talking life sciences investment trends and risks with David Sans, an investment banker with an academic background in chemical engineering and molecular modeling, and a professional background that began in Big Pharma and shifted to investing over 15 years ago. Our conversation covers patent cliff implications, hot therapeutic areas and delivery mechanisms, geopolitical risks, alternative funding strategies, and private equi...

en

34:44

Business of Biotech 2.0 with Ben Comer

Business Of Biotech ·

2025/03/31

We love to hear from our listeners. Send us a message. After nearly five years as host of the Business of Biotech podcast, Matt Pillar is handing the mic over to the voice of the Business of Biotech 2.0, veteran life sciences journalist Ben Comer. On this epsiode, Ben shares his nearly 20-year journey covering the pharmaceutical space, from Haymarket Media to PwC to Pharmaceutical Executive and InVivo magazines, before joining Life Science Connect as Chief Editor at Life Science Leader. He s...

en

43:32

BoB@JPM: Nima Farzan, Latigo Biotherapeutics

Business Of Biotech ·

2025/03/24

We love to hear from our listeners. Send us a message. In this final installment of our episodes recorded and filmed on-site at the JP Morgan Healthcare Conference, Nima Farzan, CEO of Latigo Biotherapeutics, shares his company's mission to change the pain management paradigm by way of novel, non-opioid medications that target NAV 1.8 sodium channels involved in pain signal transmission. It's a timely and important conversation that explores how these selective inhibitors could provide effec...

en

43:46

BoB@JPM: Kasper Roet, Ph.D., QurAlis

Business Of Biotech ·

2025/03/17

We love to hear from our listeners. Send us a message. Dr. Kasper Roet's hands-on work at the Dutch Brain Bank informed his leadership at the biotech QurAlis, where three clinical programs targeting specific genetic mechanisms in ALS are now underway. On this episode of the Business of Biotech, Life Science Leader's Ben Comer joins to co-host a conversation with Dr. Roet that goes deep on his company's genetic medicine approach to ALS, and even deeper into his opinions on, and growing ...

en

52:20

BoB@JPM: Rick Modi, Affinia Therapeutics

Business Of Biotech ·

2025/03/10

We love to hear from our listeners. Send us a message. The latest in our series of Business of Biotech podcasts recorded in-person at JPM in San Francisco features an inspiring conversation with Affinia Therapeutics CEO Rick Modi. Modi shares on how his upbringing in Kenya shaped his adversity-embracing worldview, and how that worldview contributes to his biotech leadership. We cover his transition from pharmaceutical work in Iowa to a career in biotech, the gene therapy advances Affinia is ...

en

56:27

BoB@JPM: Owen Hughes & Brad Sitko, XOMA Royalty

Business Of Biotech ·

2025/03/03

We love to hear from our listeners. Send us a message. On this episode of the Business of Biotech, recorded on-site at the 2025 JP Morgan Healthcare Conference, we explore a new approach to biotech financing with XOMA Royalty's Owen Hughes and Brad Sitko. The CEO and CIO, respectively, share an innovative royalty aggregation model that mitigates risk while enabling immediate capital access to biotech firms. We learn the differences between royalty financing and equity-based funding, how the ...

en

48:00

BoB@JPM: Tom Chalberg, Ph.D., Genascence

Business Of Biotech ·

2025/02/24

We love to hear from our listeners. Send us a message. Recorded in-person at the JP Morgan Healthcare Conference in San Franscisco, this episode finds Matt Pillar and Ben Comer exploring the evolution of gene therapy with Dr. Tom Chalberg, Founder, Chairman, & CEO at Genascence. We discuss ATMPS' transition from treating rare diseases to addressing common conditions like osteoarthritis, share insights on the delivery mechanism and regulatory challenges in the space, and get into the nuts...

en

37:00

BoB@JPM: Ran Zheng, Landmark Bio

Business Of Biotech ·

2025/02/17

We love to hear from our listeners. Send us a message. Ran Zhang was hire number one at Landmark Bio back in 2021. Today, she's CEO of the 70+ employee cell and gene therapy manufacturer. We caught up with her and Life Science Leader chief editor Ben Comer at the JP Morgan Healthcare Conference in San Francisco for a discussion on Landmark's role in addressing the ATMP patient access and cost reduction challenges. Along the way, we cover innovations in distributed manufacturing, non-viral ge...

en

45:07

BoB@JPM: Peter Anastasiou, Capsida Biotherapeutics

Business Of Biotech ·

2025/02/10

We love to hear from our listeners. Send us a message. From the JP Morgan Healthcare Conference in San Francisco, Peter Anastasiou, CEO of Capsida Biotherapeutics, discusses his journey from big pharma to biotech and the challenges he's faces on the leading edge of first-gneration gene therapies. Anastasiou discusses the in-house manufacturing quality advantage, how building that capacity opened the door to important partnering opportunities, the company's preparation for clinical trials and...

en

43:00

BoB@JPM: Stefan Scherer, M.D., Ph.D., 3T Bioscience

Business Of Biotech ·

2025/02/03

We love to hear from our listeners. Send us a message. From the JP Morgan Healthcare Conference in San Francisco, Dr. Stefan Scherer shares insight from 3T Bioscience's transition from clinical medicine to drug development, and his experiences in biotech leadership along the way. Dr. Scherer discusses the balance between promising advances in T-cell therapy and the challenges associated with navigating a biotech from platform development to lead candidate status -- including staffing up for ...

en

47:51

The Business Of CNS with Acumen's Jim Doherty, Ph.D.

Business Of Biotech ·

2025/01/27

We love to hear from our listeners. Send us a message. Life Science Leader's Ben Comer and Acumen Pharmaceuticals' Dr. Jim Doherty join the Business of Biotech to discuss Dr. Doherty's lifelong, singular focus on researching therapeis for CNS diseases. We cover the historical challenges associated with the development of new therapeutics for Alzheimer’s disease, advances in the space, the controversies that have ensued on the heels of recent amlyloid-targeting drug approvals, and where Acumen...

en

73:36

High-Throughput Discovery With Bioptic's Andrey Dobry

Business Of Biotech ·

2025/01/20

We love to hear from our listeners. Send us a message. Andrey Doronichev, known to many simply as Dobry, is perhaps best known for taking YouTube mobile. You heard that right. If it weren't for him and the teams he led, YouTube might still be a desktop experience. He went on to lead product strategy at Google before launching the startup Optic in 2022. What's that got to do with biotech, you ask? Well, it's Optic where he feels his greatest contributions are to come, and his sights are set sq...

en

66:32

RNA Sandbox with Johns Hopkins RNA Innovation...

Business Of Biotech ·

2025/01/13

We love to hear from our listeners. Send us a message. In close partnership woth Johns Hopkins and TriLink BioTechnologies, Jeff Coller, Ph.D. and Michelle Kim, Ph.D. have built a sandbox for RNA developers and aspirational RNA business builders to play in. On this week's episode of the Business of Biotech, we team up once again with Advancing RNA's Anna Rose Welch to learn about the venture, dubbed the Johns Hopkins University RNA Innovation Center. Anna Rose and I query Drs. Coller and Kim ...

en

54:04

Biotech Story Time With Tal Zaks, M.D. (Part 2, Tall...

Business Of Biotech ·

2025/01/06

We love to hear from our listeners. Send us a message. Dr. Tal Zaks is back, along with Advancing RNA's Anna Rose Welch, for part 2 of "Story Time With Tal." On this week's episode, we turn from his time navigating medical affairs as CMO at Moderna during the COVID 19 pandemic to learn about his latest venture, an mRNA startup called Exsilio Therapeutics. We cover the foundational aspects of the company's start, from the science it's developing, who's been recruited to the team, and how Exsil...

en

62:34

Risk Mitigation With Meira GTx's Zandy Forbes, Ph.D.

Business Of Biotech ·

2024/12/30

We love to hear from our listeners. Send us a message. Zandy Forbes, Ph.D. learned about business risk mitigation in the riskiest of business environments. She was a public markets healthcare investor on Wall Street for well more than a decade. Her hedge fund experience followed the Human Frontiers/Howard Hughes postdoctoral fellowship at the Skirball Institute of Biomolecular Medicine at NYU Langone Medical Center that was preceded by an Oxford Ph.D. in Molecular Genetics. Since 2015, she's ...

en

55:25

Biotech Story Time With Tal Zaks, M.D. (Part 1)

Business Of Biotech ·

2024/12/23

We love to hear from our listeners. Send us a message. Tal Zaks, M.D. was Chief Medical Officer at Moderna before, during, and immediately following the company's headline role during the COVID pandemic. If that doesn't pique your interest about the stories he can tell, this episode of the Business of Biotech surely will. Tal is now leading a new mRNA-centric startup called Exsilio Therapeutics, which Advancing RNA's Anna Rose Welch and I dig into in part two of our talk with Tal, slated for ...

en

52:50

A $1B AI Bet With Foresite Labs' Vik Bajaj, Ph.D.

Business Of Biotech ·

2024/12/16

We love to hear from our listeners. Send us a message. This past spring, Xaira Therapeutics launched with $1 billion in backing, a who's-who mashup of Silicon Valley and biopharma stars led by Marc Tessier-Lavigne in the C-suite, and a mission to develop AI-generated drugs. On this week's episode of the Business of Biotech, we're digging into the company's origin story and its place on the greater techbio landscape with one of the men bearing responsibility for Xaira's launch. Vik Bajaj is Ma...

en

63:50

Manufacturing Partnership With Life Biosciences'...

Business Of Biotech ·

2024/12/09

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Jerry McLaughlin, CEO and President at Life Biosciences returns for a visit, and he brought a friend in John Maslowski, newly-appointed CEO at Forge Biologics. We revisit progress at Life Biosciences, followed by a deep look into the gears that make the company's contract development and manufacturing relationship with Forge Biologics go. From CDMO selection to contracting and execution, ...

en

45:26

Novel Peptide Delivery With Revolo's Woody Bryan, Ph.D.

Business Of Biotech ·

2024/12/02

We love to hear from our listeners. Send us a message. Revolo Biotherapeutics President and CEO Woody Bryan, Ph.D. is pushing the boundaries of peptide therapeutic delivery. On this episode of the Business of Biotech, we dig into Dr. Bryan’s transition to the CEO chair at the company and how that coincided with an aggressive strategic decision to alter the course of administration of its peptide candidates in allergic and autoimmune diseases. That decision didn’t come lightly and its executio...

en

49:54

Biopolitics With Allan Shaw

Business Of Biotech ·

2024/11/25

We love to hear from our listeners. Send us a message. The notion that political influence has no place in biology appears poised for a test it hasn’t studied for. Trump administration nominations, from RFK, Jr. to HHS and Vivek Ramaswamy to the newly-proposed DOGE, are driving a storm of speculation over the implications for biotech and other life sciences industries. Throw in the increased probability of the Biosecure Act seeing the light of legislation day under a republican congress, and ...

en

289 results

Similar Podcasts

TaxTalent.com The Golden Rule Podcast

Adam Golden

TaxTalent.com Podcast

Tony Santiago

Handelsblatt Crime - spannende Streitfälle der deutschen Wirtschaft

Ina Karabasz, Solveig Gode, Sönke Iwersen

Deffner und Zschäpitz – Der Wirtschafts-Talk von WELT

WELT

Black Box - La scatola nera della finanza

Guido Brera e Gian Luca Comandini -...